Showing 51-60 of 82 results for "".
- Accure Acne Seeks to Raise Up To $20 Million Through Private Placement Offeringhttps://practicaldermatology.com/news/accure-acne-seeks-to-raise-up-to-20-million-through-private-placement-offering/2460776/Accure Acne, Inc. has launched a private placement offering on the M-Vest platform to raise up to $20 Million. Building on the research of R. Rox Anderson, MD, Accure Co-Founder and Chief Scientific & Medical Officer, Accure has developed the Accure Laser System, an&n
- Almirall’s Klisyri Performs Well in Phase III AK Trialshttps://practicaldermatology.com/news/almiralls-klisyri-performs-well-in-phase-iii-ak-trials/2460687/Almirall’s Klisyri (tirbanibulin) ointment demonstrated complete clearance of actinic keratosis (AK) lesions at day 57 in treated face or scalp areas in a significantly higher number of patients than vehicle, according to Phase III trials. What’s more, Klisyri is safe with n
- Cosentyx Shows Early Synovitis Reduction in PsAhttps://practicaldermatology.com/news/cosentyx-shows-early-synovitis-reduction-in-psa/2460600/Cosentyx (secukinumab) showed early reduction of synovitis in psoriatic arthritis (PsA), according to the Phase IIIb ULTIMATE trial which will be presented at the American College of Rheumatology (ACR) All-Virtual Annual Meeting. Specifically, a significant reduction of synovitis&n
- Positive Phase 3 Results for Dermavant's Tapinarof Cream for Plaque Psoriasishttps://practicaldermatology.com/news/positive-phase-3-results-results-for-dermavants-tapinarof-cream-for-plaque-psoriasis/2460511/Dermavant Sciences shared positive results from PSOARING 1 and PSOARING 2, two identical, multi-center, randomized, vehicle-controlled, double-blind, parallel studies to evaluate the efficacy and safety of tapinarof cream 1% in adult patients with plaque psoriasis. In both PSOARING 1 (N
- Kubota Vision, LEO Pharma A/S to Screen Novel VAP-1 Inhibitors for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases/2460351/Kubota Vision Inc. signed an Open Innovation Agreement with LEO Pharma A/S to screen novel Vascular Adhesion Protein-1 (VAP-1) inhibitor compounds for potential therapeutic use in inflammatory skin diseases, such as psoriasis and atopic dermatitis. During R&D activities to develop n
- Citing Underperformance, Hologic Sells Cynosure Medical Aesthetics Business for $205Mhttps://practicaldermatology.com/news/hologic-to-sell-cynosure-medical-aesthetics-business-for-205m/2460221/Hologic is selling Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, subject to certain closing adjustments. This is a tenth of the $1.6B that Hologic, a women's&n
- Galderma Collaborates with Nespresso to Offer Patient Loyalty Incentive Programhttps://practicaldermatology.com/news/galderma-collaborates-with-nespresso-to-offer-patient-loyalty-incentive-program/2459968/Galderma Laboratories, L.P., recently teamed up with Nespresso to offer a new rewards program for patients who seek Restylane treatments from aesthetic professionals. With a qualifying purchase of Restylane dermal fillers, aesthetic professionals will receive a set of vouchers for complimentary N
- Dr. Brandt Skincare Rolls Out Two New Productshttps://practicaldermatology.com/news/dr-brandt-skincare-rolls-out-two-new-products/2457909/Dr. Brandt skincare is introducing Hydro Biotic Recovery Sleeping Mask and Antioxidant Water Booster. The new sleeping mask is powered by Dr. Brandt Skincare's Biotic Balancing Complex, an oligosaccharide and yogurt powder that helps restore n
- FDA Approves New Eczema Drug Dupixenthttps://practicaldermatology.com/news/fda-approves-new-eczema-drug-dupixent/2458233/The FDA has approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Regeneron Pharmaceuticals, Inc.'s Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are n
- Michael R. Stewart Named Next President and CEO of MELA Scienceshttps://practicaldermatology.com/news/20141119-micheal_r_stewart_named_next_president_and_ceo_of_mela_sciences/2459057/MELA Sciences, Inc. developer of the MelaFind(R) system, a non-invasive software-driven image analysis device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, announced that its Board of Directors has named Michael R. Stewart, 57, as the company's n